Global MiRNA Sequencing and Assay Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global miRNA Sequencing and Assay Market Segmentation, By Product (Sequencing Consumables, and Library Preparation Kits), Technology (Sequencing by Synthesis, Ion Semiconductor, Solid, and Nanopore Sequencing), End-User (Clinical Laboratory, Life Science Organization, and Other End-Users)- Industry Trends and Forecast to 2032

MiRNA Sequencing and Assay Market Size

• The global miRNA sequencing and assay market size was valued at USD 425.63 million in 2024 and is expected to reach USD 1,024.11 million by 2032, at a CAGR of 11.60% during the forecast period
•  The market growth is largely fueled by the increasing adoption and technological advancements in next-generation sequencing (NGS) platforms and bioinformatics tools, which have significantly enhanced the sensitivity, throughput, and cost-efficiency of miRNA profiling. These developments are enabling more accurate detection of miRNA expression patterns, supporting research in oncology, neurology, cardiology, and rare genetic disorders
•  Furthermore, rising demand for precise, non-invasive diagnostic and prognostic tools is establishing miRNA sequencing and assays as a preferred approach for biomarker discovery and disease monitoring. These technologies are increasingly integrated into personalized medicine frameworks, where miRNA profiles guide treatment selection and disease risk stratification

MiRNA Sequencing and Assay Market Analysis

• miRNA sequencing and assay technologies, which enable the detection, profiling, and quantification of microRNAs, are becoming increasingly essential tools in both research and clinical applications. Their utility spans cancer diagnostics, neurodegenerative diseases, and biomarker discovery, offering high specificity, sensitivity, and throughput
• The growing demand for miRNA sequencing and assay tools is fueled by the rising prevalence of cancer and chronic diseases, advancements in next-generation sequencing (NGS) platforms, and increasing investments in genomic research across academic and commercial settings
• North America dominated the miRNA sequencing and assay market with the largest revenue share of 41.8% in 2024, driven by the presence of key genomic research institutions, well-established healthcare infrastructure, and government funding for precision medicine initiatives. The U.S. leads the regional market due to early adoption of NGS-based diagnostics and strong partnerships between biotech firms and research universities
• Asia-Pacific is expected to be the fastest growing region in the miRNA sequencing and assay market, with a projected CAGR of 22.4% from 2025 to 2032, propelled by rapid expansion in healthcare research, increasing patient access to molecular diagnostics, and rising investments in personalized medicine across countries such as China, Japan, and India
• The sequencing consumables segment dominated the miRNA sequencing and assay market with a market share of 57.4% in 2024, driven by the high frequency of consumable usage per sequencing run and continuous advancements in reagents that enhance read accuracy and throughput. These consumables are essential for every sequencing workflow, thereby contributing to consistent and recurring revenue generation across clinical and research applications

Report Scope and MiRNA Sequencing and Assay Market Segmentation         

MiRNA Sequencing and Assay Market Trends

“Advancing Precision Through Integrated Genomics and Diagnostic Innovation”

• A significant and accelerating trend in the global miRNA sequencing and assay market is the growing incorporation of advanced data analytics and integrated diagnostic platforms that streamline microRNA profiling and interpretation for research and clinical applications
• For instance, platforms such as QIAGEN’s QIAseq miRNA Library Kit and Illumina’s TruSeq Small RNA offer researchers robust tools to generate highly reproducible and sensitive miRNA expression profiles, aiding in the discovery of novel biomarkers and disease-specific signatures
• Advanced analytical software is now increasingly bundled with sequencing platforms, enabling real-time normalization, quality control, and differential expression analysis. These features enhance user accuracy and reduce the time required for data processing and interpretation
• Several platforms also support cloud-based workflows, providing centralized access to sequencing data, annotation databases, and collaborative tools that enable researchers and clinicians to derive insights faster and with greater consistency across institutions
• This shift toward fully integrated sequencing solutions is reshaping expectations in both academic and clinical genomics settings. Companies are increasingly offering end-to-end solutions combining miRNA sequencing reagents, instruments, and bioinformatics pipelines tailored to oncology, neurology, and infectious disease research
• The demand for platforms offering comprehensive, user-friendly, and automated miRNA analysis is expanding rapidly as researchers, pharmaceutical companies, and healthcare providers increasingly rely on miRNA-based diagnostics for early detection, disease monitoring, and therapy response evaluation

MiRNA Sequencing and Assay Market Dynamics

Driver

“Growing Demand for Precision Medicine and Advanced Molecular Diagnostics”

• The increasing focus on precision medicine, personalized therapies, and cancer genomics is a key driver fueling demand for miRNA sequencing and assay technologies. These tools enable the identification of disease-specific miRNA expression patterns, offering valuable biomarkers for early diagnosis, prognosis, and therapeutic targeting
• For instance, in March 2024, Illumina, Inc. launched its next-generation sequencing platform, NovaSeq X Plus, optimized for small RNA and miRNA profiling in oncology and immunology research. This innovation is expected to accelerate large-scale studies and strengthen Illumina’s position in the molecular diagnostics market
• In addition, rising investments in RNA-based research, coupled with the increasing prevalence of chronic diseases and cancers, are boosting the adoption of miRNA sequencing across academic, clinical, and biopharma settings
• The rising popularity of liquid biopsy and non-invasive diagnostics has also created a favorable environment for miRNA sequencing, which can be performed on biofluids such as blood or urine for real-time disease monitoring
• The integration of automated, user-friendly sequencing platforms and cloud-based data analysis tools is making miRNA sequencing more accessible to researchers and clinicians. This convenience, along with growing awareness of miRNA’s role in gene regulation, is significantly contributing to market expansion

Restraint/Challenge

“High Cost of Sequencing and Data Interpretation Complexity”

• The relatively high cost of miRNA sequencing technologies, especially for smaller labs and research groups in developing countries, remains a major barrier to widespread adoption. This includes not just equipment costs but also reagents, consumables, and the infrastructure required for high-throughput processing
• Further, the bioinformatics analysis of miRNA sequencing data is often complex and requires specialized tools and expertise. This can slow down interpretation and increase the dependency on third-party service providers
• For instance, many labs struggle with challenges in data normalization, distinguishing isomiRs, and interpreting functional significance of novel miRNAs, which hampers the utility of sequencing in clinical workflows
• Another challenge is the lack of standardization in protocols and reporting formats across different sequencing platforms and assay kits. This variation complicates cross-study comparisons and data reproducibility
• Overcoming these limitations through cost-effective kits, streamlined bioinformatics pipelines, and universal reporting guidelines will be essential for driving broader adoption of miRNA sequencing and assay solutions in both research and clinical diagnostics.

MiRNA Sequencing and Assay Market Scope

The market is segmented on the basis of product, technology, and end user.

• By Product

On the basis of product, the miRNA sequencing and assay market is segmented into sequencing consumables and library preparation kits. The sequencing consumables segment dominated the largest market revenue share of 57.4% in 2024, driven by the high frequency of consumable usage per sequencing run and continuous advancements in reagents that enhance read accuracy and throughput. These consumables are essential for every sequencing workflow, thus contributing to consistent and recurring revenue generation.

The library preparation kits segment is expected to witness the fastest CAGR of 19.6% from 2025 to 2032, attributed to the growing demand for simplified, ready-to-use kits that minimize sample preparation time and ensure reproducibility in miRNA library construction. These kits are particularly valued in clinical and translational research where sample integrity and workflow efficiency are critical.

• By Technology

On the basis of technology, the miRNA sequencing and assay market is segmented into sequencing by synthesis, ion semiconductor, solid sequencing, and nanopore sequencing. The sequencing by synthesis segment held the largest market revenue share of 48.1% in 2024, owing to its widespread adoption, high throughput capabilities, and ability to deliver precise, reliable results across diverse research and clinical settings. This method is a cornerstone of major platforms like Illumina, widely used in oncology and transcriptomic profiling.

The nanopore sequencing segment is anticipated to grow at the fastest CAGR of 21.4% during the forecast period, driven by its potential for real-time data output, long-read capabilities, and portable device formats. Researchers are increasingly adopting this technology for its minimal sample prep and ability to directly read RNA molecules.

• By End User

On the basis of end user, the miRNA sequencing and assay market is segmented into clinical laboratories, life science organizations, and other end users. The clinical laboratories segment accounted for the largest market revenue share of 44.9% in 2024, due to rising utilization of miRNA assays in cancer diagnostics, liquid biopsies, and personalized medicine initiatives. The demand is also supported by an increasing number of CLIA-certified labs integrating NGS workflows for biomarker analysis.

The life science organizations segment is projected to witness the highest CAGR of 20.3% from 2025 to 2032, fueled by expanding R&D investments in non-coding RNA research and biomarker discovery. Pharma and biotech companies are increasingly leveraging miRNA profiling to support drug development and disease pathway elucidation.

MiRNA Sequencing and Assay Market Regional Analysis

• North America dominated the miRNA sequencing and assay market, capturing the largest revenue share of 41.8% in 2024, fueled by the growing adoption of next-generation sequencing (NGS) technologies, increased focus on precision medicine, and a surge in cancer research initiatives across the region
• The region benefits from a strong presence of key players, advanced research infrastructure, and significant government and private funding directed towards genomics and transcriptomics studies
• In addition, increasing adoption of miRNA-based diagnostics in oncology and neurological disorders is driving market growth, particularly in academic research institutes and clinical laboratories

U.S. miRNA Sequencing and Assay Market Insight

The U.S. miRNA sequencing and assay market insight accounted for the largest revenue share of 81% within the North American market in 2024. The country's market dominance is attributed to robust investments in R&D, the presence of major players such as Illumina, Thermo Fisher Scientific, and widespread use of high-throughput sequencing platforms in cancer biomarker discovery. Moreover, supportive policies from NIH and other federal agencies continue to fund miRNA-related research for diagnostics and therapeutic development.

Europe miRNA Sequencing and Assay Market Insight

The Europe miRNA sequencing and assay market is projected to register a significant CAGR of 19.6% during the forecast period, driven by rising demand for advanced molecular diagnostics and increased research collaborations between academic institutes and biotech firms. European governments' investment in genomic medicine and early disease detection tools is fostering the uptake of miRNA profiling in clinical workflows.

U.K. miRNA Sequencing and Assay Market Insight

The U.K. miRNA sequencing and assay market is expected to grow at a notable CAGR of 18.3%, supported by the country’s genomics-focused healthcare strategy, such as Genomics England’s 100,000 Genomes Project, which integrates miRNA analysis to develop personalized therapies. The U.K.’s robust biotech ecosystem and strong emphasis on clinical genomics are further fueling demand for miRNA assays in diagnostics and translational research.

Germany miRNA Sequencing and Assay Market Insight

Germany miRNA sequencing and assay market is poised to expand at a CAGR of 17.9% throughout the forecast period. The country's well-established research facilities, coupled with growing investments in oncology research, are driving the adoption of miRNA sequencing technologies. Additionally, the integration of omics technologies in academic and clinical settings is enhancing the use of miRNA profiling for precision diagnostics.

Asia-Pacific miRNA Sequencing and Assay Market Insight

The Asia-Pacific miRNA sequencing and assay market region is forecasted to witness the fastest CAGR of 22.4% from 2025 to 2032. Factors contributing to this growth include increasing healthcare expenditure, expanding genomics research, and government support for personalized medicine initiatives. Countries such as China, Japan, and India are heavily investing in molecular diagnostics infrastructure and academic-industry partnerships, making miRNA sequencing more accessible and scalable.

Japan miRNA Sequencing and Assay Market Insight

The Japan miRNA sequencing and assay market is advancing rapidly due to its high-tech research infrastructure, increased incidence of age-related diseases, and growing demand for minimally invasive diagnostic tools. Integration of miRNA sequencing in early cancer detection programs and neurodegenerative disease studies is expected to drive continued growth.

China miRNA Sequencing and Assay Market Insight

China miRNA sequencing and assay market held the largest revenue share in Asia-Pacific in 2024, backed by a booming biotechnology sector, increasing investments in precision medicine, and a high prevalence of cancer. The Chinese government’s emphasis on expanding NGS infrastructure and the presence of numerous local players manufacturing cost-effective miRNA assay kits are accelerating market penetration.

MiRNA Sequencing and Assay Market Share

The miRNA sequencing and assay industry is primarily led by well-established companies, including:

•  Thermo Fisher Scientific, Inc. (U.S.)
• Illumina, Inc. (U.S.)
• QIAGEN (Netherlands)
• PerkinElmer (U.S.)
• Abcam plc (U.K.)
• New England Biolabs (U.S.)
• Takara Bio Inc. (Japan)
• Lexogen GmbH (Austria)
• Norgen Biotek Corp. (Canada)
• Maravai LifeSciences (U.S.)
• HTG Molecular Diagnostics, Inc. (U.S.)
• Meridian Bioscience, Inc. (U.S.)
• System Biosciences, LLC. (U.S.)

Latest Developments in Global MiRNA Sequencing and Assay Market

• In April 2025, BioSpyder Technologies highlighted its next-generation TempO-Seq miRNA expression profiling platform at the AACR Annual Meeting 2025, showcasing its utility in high-throughput transcriptome analysis for cancer research. The platform’s simplified workflow and scalability aim to enhance the accuracy and efficiency of miRNA sequencing, bolstering BioSpyder’s presence in the expanding global miRNA sequencing market
• In February 2025, TATAA Biocenter became a certified service provider for RealSeq Biosciences’ miRNA sequencing platform, expanding access to highly sensitive and accurate small RNA sequencing. This partnership enhances global service coverage and supports translational research in oncology and neurology by offering standardized, reproducible assays
• In March 2025, Thermo Fisher Scientific expanded its Ion Torrent Genexus System capabilities to streamline miRNA profiling workflows. The automation of sample-to-answer NGS workflows, including for small RNA libraries, supports faster turnaround times and is expected to increase adoption among clinical laboratories and research institutions globally

SKU-70401